bmf-219
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2021 (NCT05153330)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Colorectal Neoplasms · Phase 1
- Diabetes Mellitus, Type 1 · Phase 2
- Diabetes Mellitus, Type 2 · Phase 1/Phase 2
- Healthy Volunteers · Phase 1
- Leukemia · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Lymphoma · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Multiple Myeloma · Phase 1
- Mutation · Phase 1
- Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
Mechanism of action
- MeninINHIBITOR
MEN1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)N[C@@H]1CCCN(Cc2ccnc(C(=O)Nc3ccc(-c4cc5c(N6CCOCC6)ncnc5[nH]4)cc3)c2)C1- Mol. weight
- 566.67 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068392 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07254286 | Phase 1 | Sep 11, 2025 | Biomea Fusion |
| NCT06152042 | Phase 2 | Dec 31, 2023 | Biomea Fusion |
| NCT05631574 | Phase 1 | Dec 31, 2022 | Biomea Fusion |
| NCT05731544 | Phase 1/Phase 2 (Phase 2) | Aug 17, 2022 | Biomea Fusion |
| NCT05153330 | Phase 1 | Nov 30, 2021 | Biomea Fusion |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biomea Fusion | For profit | 5 | 5 | 2 | 2021 |
1 organizations
Page 1 / 1